Keros Therapeutics Inc
KROS
ISIN US4923271013 / Valor 53581630
Keros Therapeutics Inc
UMushroom community rating:
About company
Keros Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of novel therapeutics aimed at modulating the transforming growth factor-beta (TGF-β) superfamily of proteins. These regulatory proteins play a crucial role in the growth, repair, and maintenance of blood cells and various tissues. By leveraging its deep expertise in TGF-β science, Keros Therapeutics aims to create innovative treatments that offer potentially disease-modifying benefits for patients with unmet medical needs. The company's focus on TGF-β signaling positions it at the forefront of developing targeted therapies that could significantly impact patient care in areas where current treatment options are limited.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
2138 M
Market cap (USD)
91,577
Daily traded volume (Shares)
57.09 / 55.28
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
